The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trial Selector

Back

Molecule overview Clinical trials

CDK4 Inhibitor

PF-07220060 is an investigational compound. Its safety and efficacy have not been established.

Phase 1

CDK4 Inhibitor

Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung

Phase 1

NCT04557449

CDK4 Inhibitor

Breast Cancer

Phase 1

NCT06206837

CDK4 Inhibitor

Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1

NCT04606446

CDK4 Inhibitor

Breast Cancer, Solid Tumors

Phase 1

NCT05262400

Phase 2

CDK4 Inhibitor

Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung

Phase 2

NCT04557449

CDK4 Inhibitor

Breast Cancer

Phase 2

NCT06206837

CDK4 Inhibitor

Breast Cancer, Solid Tumors

Phase 2

NCT05262400

CDK4 Inhibitor

Breast Cancer

Phase 2

NCT06465368

Phase 3

CDK4 Inhibitor

Advanced or Metastatic Breast Cancer

Phase 3

NCT06105632

Clinical Trial Selector

Geo Regions

CDK4 Inhibitor

Phase 1

CDK4 Inhibitor

CDK4 Inhibitor

CDK4 Inhibitor

CDK4 Inhibitor

Phase 2

CDK4 Inhibitor

CDK4 Inhibitor

CDK4 Inhibitor

CDK4 Inhibitor

Phase 3

CDK4 Inhibitor